Retatrutide (GLP-3) Research Context — Position Within the Incretin & Glucagon Receptor Class

1. The Three Generations of Incretin Research Peptides

The published incretin-system research peptide class can be divided into three pharmacological generations, each defined by the number of receptor targets engaged by a single molecule:^{[1][3][4][14]}

• Generation 1 — GLP-1 mono-agonists (GLP-1): exenatide, liraglutide, semaglutide, lixisenatide, dulaglutide. Engineered from native GLP-1 (7–37) with peptide modifications (Aib substitution, fatty-acid conjugation) to extend the 2-minute native half-life into the hours-to-week range.^[3][5][6]
• Generation 2 — GLP-1/GIP dual agonists (GLP-2 in colloquial research nomenclature):tirzepatide. Engineered from a GIP backbone with deliberate dual-receptor activity. Demonstrated superior glycemic and body-weight effects over semaglutide in head-to-head SURPASS-2.^[7]
• Generation 3 — GIP/GLP-1/glucagon triple agonists (GLP-3 in our catalog nomenclature): Retatrutide (LY3437943) is the lead published example. The class adds glucagon receptor activation to the dual mechanism, recruiting hepatic and adipose energy-expenditure pathways absent from the prior generations.^{[1][8][11][14]}

2. Discovery Timeline of Retatrutide (GLP-3)

The intellectual lineage leading to Retatrutide (GLP-3) traces directly through the DiMarchi laboratory's pioneering work on multi-receptor unimolecular peptides:^[2][12][13]

• 2009: Day, Ottaway, Patterson and colleagues report the first GLP-1/glucagon co-agonist that eliminates obesity in rodent models — proof-of-concept for unimolecular multi-receptor design.^[12]
• 2015: Finan and colleagues publish the first rationally designed unimolecular GIP/GLP-1/glucagon triagonist that corrects obesity and diabetes in rodents.^[13]This molecule is the direct conceptual precursor to Retatrutide.
• 2020: Knerr, Mowery, Finan and colleagues describe the systematic peptide-engineering program that selected and progressed unimolecular GIP/GLP-1/glucagon agonist candidates toward clinical development.^[2]
• 2022 (May): Coskun and colleagues publish the discovery paper for LY3437943 (Retatrutide) in Cell Metabolism with full preclinical and Phase 1 human PK/PD data.^[1]
• 2022 (October): Urva and colleagues report the Phase 1b multiple-ascending-dose trial in adults with type 2 diabetes — the first multi-week human exposure data for the molecule.^[18]
• 2023 (June): Jastreboff and colleagues publish the Phase 2 obesity trial in NEJM, establishing dose-dependent body-weight reduction up to 24.2% at 48 weeks — magnitudes that had not yet plateaued at study end.^[8]
• 2023 (August): Rosenstock and colleagues publish the Phase 2 type-2-diabetes trial in The Lancet with HbA1c reductions of up to –2.02%.^[9]
• 2024 (May): Sanyal and colleagues publish the Phase 2a MASLD substudy in Nature Medicine with up to 86% relative liver-fat reduction.^[10]
• 2025: Phase 3 TRIUMPH program reads out, plus indication-specific trials including TRANSCEND-CKD (kidney), TRIUMPH-OUTCOMES (cardiovascular), and TRIUMPH-4 (knee osteoarthritis) continue to expand the research base.^{[14][15][16][17]}

3. Comparative Pharmacology — Retatrutide (GLP-3) vs Class Comparators

Cross-trial comparisons of body-weight reduction (the most consistently reported endpoint across the class) provide a clear potency hierarchy among the three generations:^{[5][7][8][14][15]}

• Generation 1 — Semaglutide (GLP-1 mono-agonist): 14.9–17.4% mean weight reduction across STEP trials at 68 weeks.^[5]
• Generation 2 — Tirzepatide (GLP-1/GIP dual): 20.9–22.5% mean weight reduction across SURMOUNT trials at 72 weeks.^[7]
• Generation 3 — Retatrutide (GLP-3, GIP/GLP-1/glucagon triple): Up to 24.2% mean weight reduction at 48 weeks in Phase 2 (with the dose-response curve still rising), and up to 28.7% mean weight reduction at 68 weeks in Phase 3 TRIUMPH-1.^{[8][14][15][17]}

The differential weight effect attributable specifically to glucagon-receptor engagement is estimated at 5–7 percentage points based on cross-trial analyses, consistent with the published hypothesis that GCGR-mediated energy expenditure adds incremental efficacy beyond what GIP and GLP-1 engagement alone can deliver.^[1][11][14]

4. Mechanistic Distinction — What GLP-3 Adds

The defining mechanistic feature of Retatrutide (GLP-3), relative to Generation 1 and Generation 2 incretin research peptides, is recruitment of the glucagon receptor (GCGR) — historically an underutilized target in incretin-system pharmacology.^[11] While glucagon was long viewed primarily as the counter-regulatory hormone to insulin, the modern reappraisal by Habegger and colleagues highlighted GCGR's additional roles in increasing energy expenditure, promoting hepatic fatty acid oxidation, and modulating satiety signaling — effects that synergize with rather than oppose insulinotropic GIP/GLP-1 actions when balanced appropriately.^[1][11]

For full receptor-binding profile, EC50 values, downstream signaling cascade detail, and tissue-level pharmacology of Retatrutide (GLP-3), see the companion Mechanism of Action deep-dive.

5. The Broader Triple-Agonist Class

Retatrutide (GLP-3) is the most clinically advanced GIP/GLP-1/glucagon unimolecular triagonist, but the broader class also includes investigational candidates from other research programs:^[14][19]

• Retatrutide (LY3437943, GLP-3): Eli Lilly. Lead candidate. Phase 3 program reading out 2025–2026.^[1][14][15]
• SAR441255: Sanofi. Reported by Bossart and colleagues in Cell Metabolism 2022 with preclinical and Phase 1 data.^[19]
• HM15211 (efinopegdutide): Hanmi Pharmaceutical. Earlier-generation candidate investigated for MASLD.^[14]
• NN9423: Novo Nordisk. Disclosed but with limited published mechanism data.^[14]

Retatrutide (GLP-3) remains the reference compound for the class given the depth of its published preclinical, Phase 1, Phase 2, and Phase 3 data set.^{[1][8][9][10][14][15]}

6. Active Research Programs Featuring Retatrutide (GLP-3)

As of 2025, the publicly registered research investigation program for Retatrutide (GLP-3)spans multiple indication-specific Phase 3 trials and adjacent preclinical studies:^{[14][15][16][17]}

• TRIUMPH-1, -2, -3, -4: Obesity and obesity-with-comorbidity Phase 3 trials.^[15][17]
• TRIUMPH-OUTCOMES: Cardiovascular outcomes Phase 3 trial.^[14][17]
• TRANSCEND-CKD: Kidney structure and function Phase 3 trial in adults with overweight or obesity and type 2 diabetes.^[16]
• TRIUMPH-4: Knee osteoarthritis Phase 3 sub-program.^[14]
• MASLD/NASH: Continued Phase 2 and emerging Phase 3 investigation following the Sanyal et al. 2024 Nature Medicine readout.^[10]
• Obstructive sleep apnea: Investigational program adjacent to obesity reduction.^[14]
• Cancer-adjacent preclinical: Tumor-engraftment-delay studies in obesity-associated cancer models.^[14]

For a research-application-by-application summary including comparator outcomes, see the companion Retatrutide (GLP-3) Research Applications deep-dive.

7. Why GLP-3 as a Catalog Name

The literature label "Retatrutide" (and its development code LY3437943) refers to the same molecule that this catalog supplies under the GLP-3 category-brand name. The naming convention reflects the third-generation position of the molecule within the incretin-system research peptide progression: GLP-1 (mono-agonists), GLP-1+GIP(dual agonists), GLP-1+GIP+Glucagon (triple agonists, our GLP-3category). PubMed citations under either "Retatrutide" or "LY3437943" resolve to the same compound supplied here as GLP-3.^[1][2][8]

8. Internal Cross-References

For the full Retatrutide (GLP-3) research collection, see the companion deep-dives: Mechanism of Action, Research Applications, Chemical Properties, and Storage & Handling. For the full product page including chemical structure, citations, and storage detail, see the Retatrutide (GLP-3) 10mg product page, also available in 20mg, 30mg, and 60mg research vials.